Welcome to CDC Stacks | HIV-associated malignancies in sub-Saharan Africa: progress, challenges, opportunities - 43904 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
HIV-associated malignancies in sub-Saharan Africa: progress, challenges, opportunities
  • Published Date:
    Jan 2017
  • Source:
    Curr Opin HIV AIDS. 12(1):89-95.


Public Access Version Available on: January 01, 2018 information icon
Please check back on the date listed above.
Details:
  • Pubmed ID:
    27607593
  • Pubmed Central ID:
    PMC5241291
  • Funding:
    K01 TW009488/TW/FIC NIH HHS/United States
    U54 CA190152/CA/NCI NIH HHS/United States
    R25 TW009340/TW/FIC NIH HHS/United States
    P20 CA210285/CA/NCI NIH HHS/United States
    P30 CA016086/CA/NCI NIH HHS/United States
    U2G PS001965/PS/NCHHSTP CDC HHS/United States
    U01 CA121947/CA/NCI NIH HHS/United States
    R21 CA180815/CA/NCI NIH HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Purpose of review

    Summarize recent developments for HIV-associated malignancies (HIVAM) in low- and middle-income countries (LMIC) with particular focus on sub-Saharan Africa (SSA).

    Recent findings

    Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers (ADC) to non-AIDS defining cancers (NADC). Despite ART scale-up, HIVAM burden remains high including enormous ADC burden in SSA. For Kaposi sarcoma (KS), patients treated with ART and chemotherapy can experience good outcomes even in rural SSA, but KS heterogeneity remains insufficiently understood including virologic, immunologic, and inflammatory features which may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including vaccination and screening is underway, with benefits already apparent despite continuing high disease burden. For non-Hodgkin lymphoma (NHL), curative treatment is possible in the ART era even in SSA, and multifaceted approaches can improve outcomes further. For many other prevalent HIVAM, care and research efforts are being established to guide treatment and prevention specifically in LMIC.

    Summary

    Sustained investment for HIVAM in LMIC can help catalyze a cancer care and research agenda which benefits HIV-positive and HIV-negative patients worldwide.

  • Supporting Files:
    No Additional Files